Indication

Immunotherapy for mite induced allergic rhinitis and allergic asthma.

Potential indication: Mite induced atopic dermatitis (under Clinical trial Phase II)

Highlights

1. Low adverse reactions, high safety;

2. Easy for storage and shipment: Our product should be kept and sealed in dark and shade place (under 20 degrees) while other desensitization drugs be stored under 2-8 degrees;

3.Noninvasive delivery, easy to operate, applicable to the children;

4. Desensitization treatment is recognized by international guidelines (by WHO in 1998 then by the ARIA consensus in 2002) 

5. Patents protected in US, EU and Japan till the end of 2027

6. Marketed in South Korea  

7. Total 19 000 000 bottles have been sold in China

Specification

Five specifications, namely No.1, No.2, No.3, No.4, No.5. 

Initiation Therapy (Up-dosing phase) :

No.1, 1 μg/ml, 2ml;

No.2, 10 μg/ml, 2ml; 

No.3, 100 μg/ml, 2ml;

Maintenance Therapy (Maintenance phase) : 

No.4, 333 μg/ml, 2ml; 

No.5 is 1000 μg/ml, 2ml 

Packing

1 vial/box